Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial – medRxiv Related: Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial – The Lancet Respiratory Medicine Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated […]

The post [Preprint] Open-label RCT: Baricitinib noninferior to Tocilizumab in hospitalized patients with severe COVID-19. appeared first on Links Medicus.